Location History:
- Aachen, DE (1998 - 2000)
- Reichelsheim, DE (2002 - 2006)
Company Filing History:
1 out of 1 
1 out of 3 
1 out of 177 
Years Active: 1998-2006
Title: Dietrich Brandenburg: Innovator in Pharmaceutical Sciences
Introduction
Dietrich Brandenburg is a notable inventor based in Reichelsheim, Germany. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative insulin analogues. With a total of five patents to his name, Brandenburg's work has the potential to impact therapeutic practices in diabetes management.
Latest Patents
Brandenburg's latest patents include groundbreaking inventions such as hepatoselective pharmaceutical actives. This invention provides an analogue of a pharmaceutical active with a molecular weight of less than 25,000 Daltons, which is covalently linked to a pendant molecular group. The result of administering this composition is an active complex with a molecular weight of 25,000 Daltons or greater present in the circulatory system. This analogue is particularly significant as it is hepatoselective when administered, with a preferred embodiment being an insulin analogue that may be used in insulin replacement therapy. Another notable patent is for covalently bridged insulin dimers, which includes a previously unknown insulin analogue and a pharmaceutical composition comprising this analogue.
Career Highlights
Throughout his career, Brandenburg has worked with various organizations, including the Deutsches Wollforschungsinstitut. His innovative research and development efforts have led to advancements in pharmaceutical formulations and therapeutic applications.
Collaborations
Brandenburg has collaborated with esteemed colleagues such as Fariba Shojaee-Moradi and Peter Henri Sonksen. These partnerships have fostered a collaborative environment that enhances the quality and impact of his research.
Conclusion
Dietrich Brandenburg's contributions to pharmaceutical sciences, particularly in the area of insulin analogues, demonstrate his commitment to innovation and improving healthcare outcomes. His patents reflect a deep understanding of molecular interactions and therapeutic needs, positioning him as a key figure in the field.